Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ACT058
MIFTS: 55

Active Peptic Ulcer Disease

Categories: Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Active Peptic Ulcer Disease

About this section

MalaCards integrated aliases for Active Peptic Ulcer Disease:

Name: Active Peptic Ulcer Disease 12 15
Gi Bleeding 12 15
Gastrointestinal Hemorrhage 70
Active Peptic Ulcer 70

Classifications:

MalaCards categories:
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:749
UMLS 70 C0017181 C1706705
Sources

Summaries for Active Peptic Ulcer Disease

About this section
MalaCards based summary : Active Peptic Ulcer Disease, also known as gi bleeding, is related to dieulafoy lesion and gastric antral vascular ectasia, and has symptoms including nausea and vomiting, constipation and vomiting. An important gene associated with Active Peptic Ulcer Disease is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Serotonergic synapse. The drugs Prucalopride and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include liver, heart and colon, and related phenotypes are homeostasis/metabolism and digestive/alimentary

Sources

Related Diseases for Active Peptic Ulcer Disease

About this section

Diseases related to Active Peptic Ulcer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 494)
# Related Disease Score Top Affiliating Genes
1 dieulafoy lesion 30.5 ATP12A VWF F2 ATP4A
2 gastric antral vascular ectasia 30.4 SST ATP4A ATP12A
3 eosinophilic gastritis 30.3 ATP4A ATP12A
4 esophagitis 30.2 PTGS2 HRH2 CYP2C19
5 gastrointestinal ulceration, recurrent, with dysfunctional platelets 30.2 PTGS2 PTGS1 HRH2
6 duodenal ulcer 30.1 SST HRH2 CYP2C19
7 gastrointestinal stromal tumor 30.0 SST PTGS2 KIT ANO1
8 intestinal tuberculosis 30.0 CRP ALB
9 angiodysplasia 30.0 VWF SST F3 ATP4A ATP12A ACVRL1
10 endocarditis 29.9 F2 CRP ALB
11 meckel diverticulum 29.9 SST KIT CRP ATP4A ALB
12 uremia 29.8 VWF CRP ALB
13 chronic intestinal vascular insufficiency 29.8 CRP ATP4A ATP12A ALB
14 ileus 29.8 SST F2 CRP
15 portal hypertension 29.8 VWF SST F3 F2 ALB
16 esophageal varix 29.8 SST F3 F2 ATP4A ATP12A ALB
17 zollinger-ellison syndrome 29.7 SST HRH2 ATP4A ATP12A
18 obstructive jaundice 29.7 KIT F2 CRP ALB
19 purpura 29.7 VWF F3 F2 CRP
20 deficiency anemia 29.7 KIT F2 CRP ATP4A ATP12A ALB
21 acquired von willebrand syndrome 29.6 VWF F7 F3 F2
22 thrombosis 29.6 VWF F7 F3 F2
23 hemorrhoid 29.6 F2 CRP ATP4A ATP12A ALB
24 intussusception 29.5 KIT CRP ANO1 ALB
25 liver cirrhosis 29.5 SST F3 F2 CRP ALB
26 intestinal obstruction 29.4 KIT CRP ATP4A ATP12A ANO1 ALB
27 peptic ulcer disease 29.4 SST PTGS2 PTGS1 HRH2 CYP2C19 ATP4A
28 acute myocardial infarction 29.3 VWF F7 F3 CRP
29 aspiration pneumonia 29.3 F3 F2 CRP ATP4A ATP12A ALB
30 gastric ulcer 29.2 SST PTGS2 PTGS1 HRH2 CYP2C19
31 gastritis 29.0 SST PTGS2 PTGS1 HRH2 CYP2C19 ATP4A
32 gastroesophageal reflux 28.9 PTGS2 PTGS1 HRH2 CYP2C19 ATP4A ATP12A
33 arthritis 28.8 PTGS2 PTGS1 HRH2 CRP ALB
34 thrombocytopenia 28.7 VWF KIT F7 F3 F2 CRP
35 vascular disease 28.3 VWF PTGS2 PTGS1 F3 F2 CYP2C19
36 myocardial infarction 27.8 VWF PTGS2 PTGS1 F7 F3 F2
37 vagus nerve disease 10.4 ATP4A ATP12A
38 scalp dermatosis 10.4 ATP4A ATP12A
39 hemangioma of intra-abdominal structure 10.4 ATP4A ATP12A
40 acquired gastric outlet stenosis 10.4 ATP4A ATP12A
41 lingual goiter 10.4 ATP4A ATP12A
42 displacement of cardia through esophageal hiatus 10.4 ATP4A ATP12A
43 bacterial esophagitis 10.4 ATP4A ATP12A
44 benzylpenicillin allergy 10.4 ATP4A ATP12A
45 cervix erosion 10.4 ATP4A ATP12A
46 angiodysplasia of intestine 10.4 ATP4A ATP12A
47 granulomatous gastritis 10.4 ATP4A ATP12A
48 laryngeal tuberculosis 10.4 ATP4A ATP12A
49 fungal esophagitis 10.4 ATP4A ATP12A
50 esophagus melanoma 10.4 ATP4A ATP12A

Comorbidity relations with Active Peptic Ulcer Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 144)


Acquired Thrombocytopenia Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Acute Pancreatitis Acute Vascular Insufficiency of Intestine
Alcohol Use Disorder Alcoholic Gastritis
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Alzheimer Disease Anus Disease
Aortic Valve Disease 1 Ascending Colon Cancer
Atrophic Gastritis Bacteremia 2
Benign Essential Hypertension Bleeding Disorder, Platelet-Type, 11
Bronchitis Bronchopneumonia
Candidiasis Cardiac Arrest
Cardiogenic Shock Cecal Benign Neoplasm
Cerebral Atherosclerosis Cerebrovascular Disease
Cholestasis Chronic Intestinal Vascular Insufficiency
Chronic Kidney Disease Chronic Pulmonary Heart Disease
Chronic Ulcer of Skin Chylomicron Retention Disease
Colon Carcinoma in Situ Colorectal Cancer
Conjunctivitis Crohn's Disease
Cystitis Decubitus Ulcer
Deficiency Anemia Dermatomycosis
Descending Colon Cancer Disseminated Intravascular Coagulation
Duodenitis Duodenum Cancer
Dysthymic Disorder Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Esophageal Cancer
Esophageal Candidiasis Esophageal Disease

Graphical network of the top 20 diseases related to Active Peptic Ulcer Disease:



Diseases related to Active Peptic Ulcer Disease
Sources

Symptoms & Phenotypes for Active Peptic Ulcer Disease

About this section

UMLS symptoms related to Active Peptic Ulcer Disease:


nausea and vomiting; constipation; vomiting; fatigue; fever; abdominal pain; hemoptysis; chest pain; headache; pruritus; syncope; diarrhea; edema; pain; nausea; chronic pain; sciatica; halitosis; dyspepsia; icterus; coughing; vertigo/dizziness; symptoms; heartburn; gastrointestinal gas; digestive system symptom; pelvic pain; blood in stool

MGI Mouse Phenotypes related to Active Peptic Ulcer Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ACVRL1 ALB ANO1 ATP12A ATP4A CRP
2 digestive/alimentary MP:0005381 10.26 ACVRL1 ALB ANO1 ATP12A ATP4A F2
3 cardiovascular system MP:0005385 10.24 ACVRL1 ALB ANO1 CRP F2 F3
4 mortality/aging MP:0010768 10.18 ACVRL1 ALB ANO1 ATP4A F2 F3
5 immune system MP:0005387 10.13 ALB ATP4A CRP F2 F3 KIT
6 muscle MP:0005369 9.97 ACVRL1 ALB ANO1 F2 F3 KIT
7 nervous system MP:0003631 9.96 ACVRL1 ANO1 F2 F3 HRH2 KIT
8 neoplasm MP:0002006 9.8 ALB ATP4A F3 KIT PTGS1 PTGS2
9 normal MP:0002873 9.76 ACVRL1 ALB F2 F3 F7 KIT
10 renal/urinary system MP:0005367 9.5 ACVRL1 ALB ANO1 ATP12A KIT PTGS1
11 respiratory system MP:0005388 9.17 ACVRL1 ANO1 F2 F3 KIT PTGS1
Sources

Drugs & Therapeutics for Active Peptic Ulcer Disease

About this section

Drugs for Active Peptic Ulcer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 188)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prucalopride Approved Phase 4 179474-81-8
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
6
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
7
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
8
Nadolol Approved Phase 4 42200-33-9 39147
9
Prazosin Approved Phase 4 19216-56-9 4893
10
Nitric Oxide Approved Phase 4 10102-43-9 145068
11
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
12
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
13
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
14
Warfarin Approved Phase 4 81-81-2 6691 54678486
15
Vitamin K1 Approved, Investigational Phase 4 84-80-0 5284607
16 Bemiparin Approved, Investigational Phase 4 91449-79-5
17
Thrombin Approved, Investigational Phase 4
18
Dalteparin Approved Phase 4 9005-49-6
19
Heparin Approved, Investigational Phase 4 9005-49-6 772 9812414
20
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
21
Linaclotide Approved Phase 4 851199-59-2 65351
22
Sucralfate Approved Phase 4 54182-58-0
23
Midodrine Approved Phase 4 42794-76-3, 133163-28-7 4195
24
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
25
Misoprostol Approved Phase 4 59122-46-2 5282381
26
Metronidazole Approved Phase 4 443-48-1 4173
27
Ofloxacin Approved Phase 4 82419-36-1 4583
28
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
29
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
30
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
31
Famotidine Approved Phase 4 76824-35-6 3325
32
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
33
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
34
Pantoprazole Approved Phase 4 102625-70-7 4679
35
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
36
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
37
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
38 Menaquinone Investigational Phase 4 1182-68-9
39 Coagulants Phase 4
40 Cathartics Phase 4
41 Serotonin Receptor Agonists Phase 4
42 Laxatives Phase 4
43 Antifibrinolytic Agents Phase 4
44 Purinergic P2Y Receptor Antagonists Phase 4
45 Platelet Aggregation Inhibitors Phase 4
46 Hormones Phase 4
47 Hormone Antagonists Phase 4
48 diuretics Phase 4
49 Vasodilator Agents Phase 4
50 Anti-Arrhythmia Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 236)
# Name Status NCT ID Phase Drugs
1 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial Unknown status NCT01549418 Phase 4 Aspirin (ASA);Placebo
2 The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial Unknown status NCT02806206 Phase 4 Prucalopride;Placebo
3 The Comparison of Oral Rabeprazole vs. Intravenous Omeprazole in the Treatment of Patients With Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT00861640 Phase 4 Intravenous Omeprazole;Oral Rabeprazole
4 A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding Unknown status NCT01275937 Phase 4 Esomeprazole;esomeprazole
5 Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding Unknown status NCT02537353 Phase 4 Hemospray;Adrenaline
6 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Unknown status NCT03023189 Phase 4 Tranexamic acid;Placebo
7 Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding. Unknown status NCT00414713 Phase 4
8 Randomized Controlled Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding Completed NCT01006824 Phase 4
9 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
10 Appropriate Time Interval for Repeat Sessions of Endoscopic Ligation for the Eradication of Esophageal Varices Completed NCT01291277 Phase 4
11 A Multi-centre Proof of Concept Study to Assess Efficacy and Safety of a New Liquid Endoscopic Hemostatic Agent (Seraseal / Fastact ®) in Patients With Active Gastrointestinal Bleeding Completed NCT02349490 Phase 4
12 Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection -a Prospective Randomized Controlled Study Completed NCT01914692 Phase 4 Somatostatin
13 Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy Completed NCT02718261 Phase 4 Pantoprazole;Saline 0.9% (matching placebo)
14 A Randomized, Controlled, Multicentric Trial Comparing Endoscopic Band Ligation Versus Ransjugular Intrahepatic Portosystemic Stent Shunt in Cirrhotic Patients With Recurrent Variceal Bleeding Non Responding to Medical Therapy Completed NCT00570973 Phase 4
15 Single Blind, Randomized, Controlled Trial of Conventional Versus Split-Dose Bowel Preparation for Inpatient Colonoscopy Completed NCT01169220 Phase 4 Go-Lytely;Go Lytely
16 Comparison of the Efficacy of Compliant Oral Iron Treatment (FerroDuretter ®) for 3 Months After Discharge Versus Single-dose of Intravenous Iron (Ferinject ®) Before Discharge in Patients With Acute Bleeding From Upper Gastrointestinal Tract. A Double Blinded Randomized Trial Completed NCT00978575 Phase 4 ferricarboxymaltose;Ferrosulfate;Placebo
17 Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage: A Double-Blind, Randomized, Placebo-Controlled Trial Completed NCT02903017 Phase 4 Tranexamic acid 5%;Placebo
18 Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response. Completed NCT00450164 Phase 4 Nadolol;Isosorbide mononitrate;Prazosin
19 Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer. Completed NCT02638584 Phase 4 Ilaprazole;Rabeprazole
20 The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy Completed NCT00840008 Phase 4
21 Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding. Completed NCT01727453 Phase 4 warfarin;Bemiparina
22 A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding Completed NCT01654770 Phase 4
23 Single-dose Linaclotide for Capsule Endoscopy Preparation Completed NCT02465385 Phase 4 Linaclotide
24 Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU) Completed NCT02467621 Phase 4 Pantoprazole
25 A Prospective, Randomized, Double-blind, Double-dummy, Sucralfate Controlled, Multicenter Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis Completed NCT01284647 Phase 4 Teprenone capsule and placebo of sucralfate;Sucralfate and placebo of teprenone
26 Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
27 Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding Completed NCT00838864 Phase 4 ceftrioxone;ceftrioxone
28 Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine Completed NCT00950339 Phase 4 omeprazole, 20mg twice daily;famotidine 40mg twice daily;pantoprazole 40mg once daily
29 The Protection of Telipression on Developing of Acute Kidney Injury in Cirrhotic Patients With Upper-gastroentestinal Bleeding Completed NCT04358016 Phase 4 Terlipressin;Somatostatin
30 Effects of Different Omeprazole Dosing on Gastric pH in Non- Variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study Completed NCT03980496 Phase 4 Omeprazole
31 Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study. Completed NCT00164866 Phase 4 Omeprazole
32 Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding Completed NCT01806090 Phase 4 clopidogrel
33 Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer: a Double-blind Randomised Trial on Misoprostol Combined With Lansoprazole Versus Lansoprazole Alone (NRT_MISO Study) Recruiting NCT03675672 Phase 4 Misoprostol Oral Tablet;Placebo Oral Tablet
34 Intravenous Administration of Metronidazole, Levofloxacin and Esomeprazole Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease Recruiting NCT04432233 Phase 4 Esomeprazole;Metronidazole;Levofloxacin
35 Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study Recruiting NCT03624517 Phase 4 Octreotide
36 Stress Ulcer Prophylaxis Versus Placebo - a Blinded Randomized Control Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease Recruiting NCT03667703 Phase 4 Famotidine;Placebo
37 A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease Not yet recruiting NCT04416581 Phase 4 PPI;P-CAB 25;P-CAB 50
38 The Efficacy of Metoclopramide for Gastric Visualization by Endoscopy in Patients With Acute Upper Gastrointestinal Bleeding: Double-blind Randomized Controlled Trial Not yet recruiting NCT04771481 Phase 4 Metoclopramide;Normal Saline 10 mL Injection
39 The Effect of Vonoprazan-based Dual Eradication Therapy vs PPI Treatment on Gastrointestinal Bleeding in ACS Patients With Hp Infection and Coronary Stents: an Open-label, Randomized, Controlled Trial Not yet recruiting NCT04728516 Phase 4 Vonoprazan-based dual eradication therapy for two weeks;amoxicillin;Pantoprazole
40 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
41 Oral vs Intravenous Proton Pump Inhibitor（PPI） in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial Withdrawn NCT01123031 Phase 4 lansoprazole;esomeprazole
42 Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopic Examination in Patients With Upper Gastrointestinal Bleeding. A Prospective Randomized Trial. Unknown status NCT01716572 Phase 3 Erythromycin
43 Early Administration of Intravenous Tranexamic Acid for Upper Gastrointestinal Bleeding Prior to Endoscopy Unknown status NCT01713101 Phase 3 Early intravenous tranexamic acid administration;placebo
44 Peri-operative Usage of Enteric Immune-nutrition Formula (ANOM®) Versus Standard Formula for Patients Received Major Upper Gastrointestinal Surgery Unknown status NCT01351883 Phase 3
45 Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage Unknown status NCT00553423 Phase 3 Lactulose;Placebo
46 Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding Unknown status NCT01628068 Phase 3
47 A Multicenter, Randomized, Open-label Clinical Trial Assessing the Efficacy of Octreotide in Decreasing Blood and Iron Requirements in Patients With Refractory Anaemia Due to Angiodysplasias Unknown status NCT02384122 Phase 2, Phase 3 Octreotide
48 A Randomised Study of the Optimal Bowel Preparation for Routine Capsule Endoscopy Using Citramag and Senna or Metoclopramide Unknown status NCT00275184 Phase 3 Senna;Citramag powder;Metoclopramide
49 Emergency Capsule Endoscopy in Severe GI-bleeding Completed NCT01584869 Phase 2, Phase 3
50 Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill Completed NCT00045799 Phase 3 Omeprazole sodium bicarbonate immediate release PWD/FS;Cimetidine IV

Search NIH Clinical Center for Active Peptic Ulcer Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aluminum carbonate
Aluminum Hydroxide
Aluminum Hydroxide / Magnesium Hydroxide
Aluminum Hydroxide Gel
aluminum hydroxide, dried (USP)
basic aluminum carbonate gel
Calcium Carbonate
CALCIUM CARBONATE 1 g in 1 g ORAL POWDER
Calcium gluceptate
dihydroxyaluminum sodium carbonate
magaldrate
Magnesium Hydroxide
MILK OF MAGNESIA
Vasopressin (USP)
VASOPRESSIN TANNATE (IN OIL)
Sources

Genetic Tests for Active Peptic Ulcer Disease

About this section
Sources

Anatomical Context for Active Peptic Ulcer Disease

About this section

MalaCards organs/tissues related to Active Peptic Ulcer Disease:

40
Liver, Heart, Colon, Small Intestine, Pancreas, Bone, Kidney
Sources

Publications for Active Peptic Ulcer Disease

About this section

Articles related to Active Peptic Ulcer Disease:

(show top 50) (show all 3076)
# Title Authors PMID Year
1
Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation. 61
33404923 2021
2
Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. 61
32747412 2021
3
Eosinophilic colitis in children: a new and elusive enemy? 61
33409540 2021
4
Prophylactic clips to reduce delayed polypectomy bleeding after resection of large colorectal polyps: a systematic review and meta-analysis of randomized trials. 61
33049265 2021
5
Management of Non-Variceal Upper GI Bleeding in the Geriatric Population: An Update. 61
33768344 2021
6
A tricky upper GI bleeding: duodenal intra-diverticular angioectasia treated by endoscopic band ligation. 61
33731312 2021
7
Evaluating the impact of frailty on periprocedural adverse events and mortality among patients with GI bleeding. 61
33753111 2021
8
Predictive performance of blood urea nitrogen to serum albumin ratio in elderly patients with gastrointestinal bleeding. 61
33465709 2021
9
The Effect of Age on Outcomes After Destination-Therapy Left Ventricular Assist Device Implantation: An Analysis of the IMACS Registry. 61
32585330 2021
10
Efficacy and safety of proton pump inhibitors combined with clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis. 61
33792258 2021
11
Endoscopic management of early GI tract bleeding in a group of bariatric patients undergoing a fast track protocol. 61
33786127 2021
12
Gastrointestinal manifestations in COVID-19. 61
33728439 2021
13
Post-transfusion hemoglobin response in patients with cirrhosis: Can we expect a 1 g/dL rise per unit transfused? 61
33372691 2021
14
Perspectives of Inpatients with Cirrhosis and Caregivers on Using Health Information Technology: A Cross-Sectional Multi-Center Experience. 61
33744844 2021
15
Depression, HPV Immunizations, Coccidioidomycosis, Upper GI Bleeding, Headaches. 61
33719373 2021
16
Effectiveness of metronidazole gel and mobile telephone short-message service reminders on gingivitis in orthodontic patients. 61
33378447 2021
17
A Two-week Single-group Longitudinal Test of a New Sonic Powered Toothbrush Simulating the "Bass Brushing Technique" with Tapered Bristles on the Brush Head for Reduction of Dental Plaque and Gingivitis. 61
33768685 2021
18
Gastrointestinal bleeding increases the risk of subsequent cardiovascular events in patients with acute cardiovascular diseases requiring intensive care. 61
33683409 2021
19
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis. 61
33726018 2021
20
A Rare and Severe Presentation of Henoch-Schönlein Purpura in an Adolescent With Crescentic Glomerulonephritis, Arrhythmia, Acute Gastrointestinal Bleed, and Neurological Complications. 61
33796429 2021
21
Gastrointestinal Hemorrhage: A Manifestation of the Telomere Biology Disorders. 61
32971146 2021
22
Gastroprotection in patients on antiplatelet and/or anticoagulant therapy: a position paper of National Association of Hospital Cardiologists (ANMCO) and the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO). 61
33279389 2021
23
Robotic duodenal (D3) resection with Roux-en-Y duodenojejunostomy reconstruction for large GIST tumor: Step by step with video. 61
33370658 2021
24
Readmissions Rates After Myocardial Infarction for Gastrointestinal Bleeding: A National Perspective. 61
32436123 2021
25
An unusual presentation of portal vein thrombosis in a 2-year-old girl. 61
32829990 2021
26
The prevalence of small-bowel polyps on video capsule endoscopy in patients with sporadic duodenal or ampullary adenomas. 61
32717365 2021
27
Intracardiac echocardiography-guided implantation of the Watchman FLX left atrial appendage closure device. 61
33533089 2021
28
Drug-drug Interactions with Warfarin: A Systematic Review and Meta-analysis. 61
33769581 2021
29
Transcatheter and Endoscopic Treatment of Gastric and Duodenal Bleeding: Population-Based Analysis of National Inpatient Trends and Outcomes in the United States. 61
32890494 2021
30
Nutritional medical therapy in cachexia patient with oesophageal adenocarcinoma metastases on dexamethasone therapy: A case report. 61
33785960 2021
31
Revisiting Quincke's Triad: A Case of Idiopathic Hepatic Artery Aneurysm Presenting with Obstructive Jaundice. 61
33157248 2021
32
Predictors of gastrointestinal bleeding in adult ICU patients in the SUP-ICU trial. 61
33635540 2021
33
Gastrointestinal bleeding from angiodysplasia in von Willebrand disease: Improved diagnosis and outcome prediction using videocapsule on top of conventional endoscopy. 61
33113216 2021
34
Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study. 61
33627313 2021
35
Impact of bleeding complications after transcatheter mitral valve repair. 61
33457493 2021
36
Accuracy of noninvasive tests in the prediction of portal hypertensive gastropathy in Egyptian patients with cirrhosis. 61
33553669 2021
37
Preservation of Organ Function in Locally Advanced Non-Metastatic Gastrointestinal Stromal Tumors (GIST) of the Stomach by Neoadjuvant Imatinib Therapy. 61
33546113 2021
38
Hospital outcomes and early readmission for the most common gastrointestinal and liver diseases in the United States: Implications for healthcare delivery. 61
33643534 2021
39
Upper Gastrointestinal Bleeding. 61
33213769 2021
40
Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a systematic review and meta-analysis. 61
33523277 2021
41
Low-Dose vs Regular-Dose Aspirin for Venous Thromboembolism Prophylaxis in Primary Total Joint Arthroplasty. 61
33640184 2021
42
Primary Aorto-Duodenal Fistula in Association with Chronic Ischemic Enteritis: A Case Report. 61
33549790 2021
43
Intermittent concurrent use of clopidogrel and proton pump inhibitors did not increase risk of adverse clinical outcomes in Chinese patients with coronary artery disease. 61
33546595 2021
44
Tamoxifen Therapy for Recurrent Mucosal Bleeding in Hereditary Hemorrhagic Telangiectasia. 61
33643506 2021
45
Antibacterial coating of tooth surface with ion-releasing pre-reacted glass-ionomer (S-PRG) nanofillers. 61
33644453 2021
46
Fluoroscopy-guided endoscopic sclerotherapy: a novel hybrid approach for symptomatic rectosigmoidal venous malformation (with video). 61
32553568 2021
47
Effect of an emergency department intensive care unit on medical intensive unit admissions and care: A retrospective cohort study. 61
33714051 2021
48
Clinical and endoscopic features of aorto-duodenal fistula resulting in its definitive diagnosis: an observational study. 61
33526013 2021
49
Dieulafoy's lesion of the upper GI tract: a comprehensive nationwide database analysis. 61
33359438 2021
50
Daily aspirin for primary prevention increased risk for major GI bleeding in healthy older adults. 61
33395330 2021
Sources

Variations for Active Peptic Ulcer Disease

About this section
Sources

Expression for Active Peptic Ulcer Disease

About this section
Search GEO for disease gene expression data for Active Peptic Ulcer Disease.
Sources

Pathways for Active Peptic Ulcer Disease

About this section

Pathways related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Formation of Fibrin Clot (Clotting Cascade) 65
Show member pathways
 11.82 VWF F7 F3 F2
2
Serotonergic synapse 36
11.73 PTGS2 PTGS1 CYP2C19
3
Complement and coagulation cascades 36 1
11.72 VWF F7 F3 F2
4
Linoleic acid metabolism 36
Show member pathways
 11.71 PTGS2 PTGS1 CYP2C19
5
Angiogenesis (CST) 4
11.53 VWF PTGS2 F3
6
Selenium Micronutrient Network 1
Show member pathways
 11.43 PTGS2 PTGS1 F7 F2 CRP ALB
7
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
10.96 VWF PTGS1 F2 CYP2C19
8
Warfarin Pathway, Pharmacodynamics 60
10.63 F7 F2
9
Etoposide Pathway, Pharmacokinetics/Pharmacodynamics 60
10.61 PTGS2 PTGS1
10
Overview of nanoparticle effects 1
10.61 PTGS2 PTGS1 CRP
11
Secretion of Hydrochloric Acid in Parietal Cells 1
10.07 HRH2 ATP4A
Sources

GO Terms for Active Peptic Ulcer Disease

About this section

Cellular components related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.46 PTGS2 F7 F2 ALB
2 organelle membrane GO:0031090 9.43 PTGS2 PTGS1 CYP2C19
3 extracellular space GO:0005615 9.28 VWF SST KIT F7 F3 F2
4 serine-type peptidase complex GO:1905286 8.96 F7 F3

Biological processes related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.56 VWF F7 F3 F2
2 blood coagulation, intrinsic pathway GO:0007597 9.54 VWF F2
3 cellular oxidant detoxification GO:0098869 9.54 PTGS2 PTGS1 ALB
4 negative regulation of programmed cell death GO:0043069 9.52 KIT ALB
5 positive regulation of blood coagulation GO:0030194 9.51 F7 F2
6 regulation of blood pressure GO:0008217 9.5 PTGS2 PTGS1 ACVRL1
7 sodium ion export across plasma membrane GO:0036376 9.49 ATP4A ATP12A
8 cellular potassium ion homeostasis GO:0030007 9.48 ATP4A ATP12A
9 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.46 ATP4A ATP12A
10 positive regulation of positive chemotaxis GO:0050927 9.43 F7 F3
11 cyclooxygenase pathway GO:0019371 9.4 PTGS2 PTGS1
12 positive regulation of platelet-derived growth factor receptor signaling pathway GO:0010641 9.16 F7 F3
13 blood coagulation, extrinsic pathway GO:0007598 8.96 F7 F3
14 hemostasis GO:0007599 8.92 VWF F7 F3 F2

Molecular functions related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.96 PTGS2 PTGS1 KIT CYP2C19 CRP ATP4A
2 protease binding GO:0002020 9.54 VWF KIT F3
3 sodium:potassium-exchanging ATPase activity GO:0005391 9.32 ATP4A ATP12A
4 potassium-transporting ATPase activity GO:0008556 9.16 ATP4A ATP12A
5 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP4A ATP12A
6 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS2 PTGS1
Sources

Sources for Active Peptic Ulcer Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....